Table 1. Demographic features, clinical and laboratory manifestations and treatment of 120 SLE patients.
| Clinical manifestations—N (%) | |
| Skin involvement | 88 (73.3) |
| Serositis | 21 (17.5) |
| Hematological manifestations | 72 (60.0) |
| Neuropsychiatric involvement | 11 (9.2) |
| Renal involvement | 28 (23.3) |
| Laboratory manifestations—N (%) | |
| Anti-DNA | 86 (71.7) |
| Anti-Sm | 19 (15.8) |
| Anti-SSA | 43 (35.8) |
| Anti-SSB | 26 (21.7) |
| Anti-RNP | 17 (14.2) |
| Anti-Cardiolipin IgG/IgM | 44 (36.7) |
| Anti-β2 Glycoprotein I IgG/IgM | 30 (25.0) |
| Lupus Anticoagulant | 34 (28.3) |
| Low C3/C4 levels | 66 (55.0) |
| Treatments—N (%) | |
| Glucocorticoids | 108 (90.0) |
| Hydroxychloroquine | 112 (93.3) |
| Cyclosporine A | 28 (23.3) |
| Methotrexate | 41 (34.2) |
| Cyclophosphamide | 6 (5.0) |
| Mycophenolate Mofetil | 31 (25.8) |
| Azathioprine | 26 (21.7) |
| Rituximab | 5 (4.2) |
| Belimumab | 5 (4.2) |